Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.

Janka Ryding, L Dahlberg, M Wallen-Ohman, Joakim Dillner

Research output: Contribution to journalArticlepeer-review

26 Citations (SciVal)

Abstract

Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.
Original languageEnglish
Pages (from-to)792-802
JournalJournal of General Virology
Volume88
Issue numberPt 3
DOIs
Publication statusPublished - 2007

Subject classification (UKÄ)

  • Microbiology in the medical area

Fingerprint

Dive into the research topics of 'Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.'. Together they form a unique fingerprint.

Cite this